Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial.
Yoshiaki IwasakiMasanori TerashimaJunki MizusawaHiroshi KatayamaKenichi NakamuraHitoshi KataiTakaki YoshikawaSeiji ItoMasahide KajiYutaka KimuraMotohiro HiraoMakoto YamadaAkira KuritaMasakazu TakagiSang-Woong LeeAkinori TakaganeHiroshi YabusakiJun HiharaNarikazu BokuTakeshi SanoMitsuru SasakoPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2020)
For type 4 or large type 3 gastric cancer, NAC with S-1 plus cisplatin failed to demonstrate a survival benefit. D2 surgery followed by adjuvant chemotherapy remains the standard treatment.